View Item 

Show simple item record

Safety of Plasma Infusions in Parkinson’s Disease
dc.contributor.authorParker, Jordan E.
dc.contributor.authorMartinez, Amaris
dc.contributor.authorDeutsch, Gayle K.
dc.contributor.authorPrabhakar, Varsha
dc.contributor.authorLising, Melanie
dc.contributor.authorKapphahn, Kristopher I.
dc.contributor.authorAnidi, Chioma M.
dc.contributor.authorNeuville, Raumin
dc.contributor.authorCoburn, Maria
dc.contributor.authorShah, Neil
dc.contributor.authorBronte‐stewart, Helen M.
dc.date.accessioned2020-12-02T14:36:09Z
dc.date.availableWITHHELD_12_MONTHS
dc.date.available2020-12-02T14:36:09Z
dc.date.issued2020-11
dc.identifier.citationParker, Jordan E.; Martinez, Amaris; Deutsch, Gayle K.; Prabhakar, Varsha; Lising, Melanie; Kapphahn, Kristopher I.; Anidi, Chioma M.; Neuville, Raumin; Coburn, Maria; Shah, Neil; Bronte‐stewart, Helen M. (2020). "Safety of Plasma Infusions in Parkinson’s Disease." Movement Disorders 35(11): 1905-1913.
dc.identifier.issn0885-3185
dc.identifier.issn1531-8257
dc.identifier.urihttps://hdl.handle.net/2027.42/163536
dc.description.abstractBackgroundYoung plasma infusions have emerged as a potential treatment for neurodegenerative disease, and convalescent plasma therapy has been used safely in the management of viral pandemics. However, the effect of plasma therapy in Parkinson’s disease (PD) is unknown.ObjectivesThe objective of this study was to determine the safety, tolerability, and feasibility of plasma infusions in people with PD.MethodsA total of 15 people with clinically established PD, at least 1 cognitive complaint, and on stable therapy received 1 unit of young fresh frozen plasma twice a week for 4- weeks. Assessments and adverse effects were performed/reported on and off therapy at baseline, immediately after, and 4- weeks after the infusions ended. Adverse effects were also assessed during infusions. The primary outcomes were safety, tolerability, and feasibility. Exploratory outcomes included Unified Parkinson’s Disease Rating Scale Part III off medication, neuropsychological battery, Parkinson’s Disease Questionnaire- 39, inflammatory markers (tumor necrosis factor- α, interleukin- 6), uric acid, and quantitative kinematics.ResultsAdherence rate was 100% with no serious adverse effects. There was evidence of improvement in phonemic fluency (P = 0.002) and in the Parkinson’s Disease Questionnaire- 39 stigma subscore (P = 0.013) that were maintained at the delayed evaluation. Elevated baseline tumor necrosis factor- α levels decreased 4- weeks after the infusions ended.ConclusionsYoung fresh frozen plasma was safe, feasible, and well tolerated in people with PD, without serious adverse effects and with preliminary evidence for improvements in phonemic fluency and stigma. The results of this study warrant further therapeutic investigations in PD and provide safety and feasibility data for plasma therapy in people with PD who may be at higher risk for severe complications of COVID- 19. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.otherParkinson’s disease
dc.subject.otherplasma
dc.subject.otheryoung plasma
dc.subject.otherinfusions
dc.titleSafety of Plasma Infusions in Parkinson’s Disease
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163536/2/mds28198.pdfen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163536/1/mds28198_am.pdfen_US
dc.identifier.doi10.1002/mds.28198
dc.identifier.sourceMovement Disorders
dc.identifier.citedreferenceMiyake A, Friedman NP. The nature and organization of individual differences in executive functions: four general conclusions. Curr Dir Psychol Sci 2012; 21 ( 1 ): 8 - 14. https://doi.org/10.1177/0963721411429458
dc.identifier.citedreferenceDe Virgilio A, Greco A, Fabbrini G, et al. Parkinson’s disease: autoimmunity and neuroinflammation. Autoimmun Rev 2016; 15 ( 10 ): 1005 - 1011. https://doi.org/10.1016/j.autrev.2016.07.022
dc.identifier.citedreferenceNasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53 ( 4 ): 695 - 699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
dc.identifier.citedreferenceHoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17 ( 5 ): 427 - 442.
dc.identifier.citedreferenceTrager MH, Koop MM, Velisar A, et al. Subthalamic beta oscillations are attenuated after withdrawal of chronic high frequency neurostimulation in Parkinson’s disease. Neurobiol Dis 2016; 96: 22 - 30. https://doi.org/10.1016/j.nbd.2016.08.003
dc.identifier.citedreferenceGoetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society- sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS- UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23 ( 15 ): 2129 - 2170. https://doi.org/10.1002/mds.22340
dc.identifier.citedreferenceHarris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)- a metadata- driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 ( 2 ): 377 - 381. https://doi.org/10.1016/j.jbi.2008.08.010
dc.identifier.citedreferenceR Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2018.
dc.identifier.citedreferencePostuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30 ( 12 ): 1591 - 1601. https://doi.org/10.1002/mds.26424
dc.identifier.citedreferenceShulman LM, Gruber- Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the Unified Parkinson’s Disease Rating Scale. Arch Neurol 2010; 67 ( 1 ): 64 - 70. https://doi.org/10.1001/archneurol.2009.295
dc.identifier.citedreferencePandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012; 52 ( suppl 1 ): 65S - 79S. https://doi.org/10.1111/j.1537-2995.2012.03663.x
dc.identifier.citedreferenceLitvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27 ( 3 ): 349 - 356. https://doi.org/10.1002/mds.24893
dc.identifier.citedreferenceHenry JD, Crawford JR. Verbal fluency deficits in Parkinson’s disease: a meta- analysis. J Int Neuropsychol Soc 2004; 10 ( 4 ): 608 - 622. https://doi.org/10.1017/S1355617704104141
dc.identifier.citedreferenceJaywant A, Musto G, Neargarder S, Gilbert KS, Cronin- Golomb A. The effect of Parkinson’s disease subgroups on verbal and nonverbal fluency. J Clin Exp Neuropsychol 2014; 36 ( 3 ): 278 - 289. https://doi.org/10.1080/13803395.2014.889089
dc.identifier.citedreferenceShao Z, Janse E, Visser K, Meyer AS. What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults. Front Psychol 2014; 5: 772. https://doi.org/10.3389/fpsyg.2014.00772
dc.identifier.citedreferenceEllfolk U, Joutsa J, Rinne JO, Parkkola R, Jokinen P, Karrasch M. Striatal volume is related to phonemic verbal fluency but not to semantic or alternating verbal fluency in early Parkinson’s disease. J Neural Transm 2014; 121 ( 1 ): 33 - 40. https://doi.org/10.1007/s00702-013-1073-2
dc.identifier.citedreferenceTröster AI. Some clinically useful information that neuropsychology provides patients, carepartners, neurologists, and neurosurgeons about deep brain stimulation for Parkinson’s disease. Arch Clin Neuropsychol 2017; 32 ( 7 ): 810 - 828. https://doi.org/10.1093/arclin/acx090
dc.identifier.citedreferenceBraak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24 ( 2 ): 197 - 211.
dc.identifier.citedreferenceBouchard J, Villeda SA. Aging and brain rejuvenation as systemic events. J Neurochem 2015; 132 ( 1 ): 5 - 19. https://doi.org/10.1111/jnc.12969
dc.identifier.citedreferenceRao D, Choi SW, Victorson D, et al. Measuring stigma across neurological conditions: the development of the Stigma Scale for Chronic Illness (SSCI). Qual Life Res 2009; 18 ( 5 ): 585 - 595. https://doi.org/10.1007/s11136-009-9475-1
dc.identifier.citedreferenceMa H- I, Saint- Hilaire M, Thomas CA, Tickle- Degnen L. Stigma as a key determinant of health- related quality of life in Parkinson’s disease. Qual Life Res 2016; 25 ( 12 ): 3037 - 3045. https://doi.org/10.1007/s11136-016-1329-z
dc.identifier.citedreferenceBarcia C, de Pablos V, Bautista- Hernández V, et al. Increased plasma levels of TNF- α but not of IL1- β in MPTP- treated monkeys one year after the MPTP administration. Parkinsonism Relat Disord 2005; 11 ( 7 ): 435 - 439. https://doi.org/10.1016/j.parkreldis.2005.05.006
dc.identifier.citedreferenceBoka G, Anglade P, Wallach D, Javoy- Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 1994; 172 ( 1- 2 ): 151 - 154. https://doi.org/10.1016/0304-3940(94)90684-x
dc.identifier.citedreferenceHunot S, Dugas N, Faucheux B, et al. FcepsilonRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor- alpha in glial cells. J Neurosci 1999; 19 ( 9 ): 3440 - 3447.
dc.identifier.citedreferenceMogi M, Kondo A, Kinpara K, Togari A. Anti- apoptotic action of nerve growth factor in mouse osteoblastic cell line. Life Sci 2000; 67 ( 10 ): 1197 - 1206. https://doi.org/10.1016/s0024-3205(00)00705-0
dc.identifier.citedreferenceNagatsu T, Sawada M. Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des 2005; 11 ( 8 ): 999 - 1016.
dc.identifier.citedreferenceSriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O’Callaghan JP. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson’s disease. FASEB J 2002; 16 ( 11 ): 1474 - 1476. https://doi.org/10.1096/fj.02-0216fje
dc.identifier.citedreferenceMcCoy MK, Martinez TN, Ruhn KA, et al. Blocking soluble tumor necrosis factor signaling with dominant- negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson’s disease. J Neurosci 2006; 26 ( 37 ): 9365 - 9375. https://doi.org/10.1523/JNEUROSCI.1504-06.2006
dc.identifier.citedreferenceVilleda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011; 477 ( 7362 ): 90 - 94. https://doi.org/10.1038/nature10357
dc.identifier.citedreferenceVilleda SA, Plambeck KE, Middeldorp J, et al. Young blood reverses age- related impairments in cognitive function and synaptic plasticity in mice. Nat Med 2014; 20 ( 6 ): 659 - 663. https://doi.org/10.1038/nm.3569
dc.identifier.citedreferenceMiddeldorp J, Lehallier B, Villeda SA, et al. Preclinical assessment of young blood plasma for Alzheimer disease. JAMA Neurol 2016; 73 ( 11 ): 1325 - 1333. https://doi.org/10.1001/jamaneurol.2016.3185
dc.identifier.citedreferenceKim H- J, Yeom JS, Koh Y- G, et al. Anti- inflammatory effect of platelet- rich plasma on nucleus pulposus cells with response of TNF- α and IL- 1. J Orthop Res 2014; 32 ( 4 ): 551 - 556. https://doi.org/10.1002/jor.22532
dc.identifier.citedreferenceSha SJ, Deutsch GK, Tian L, et al. Safety, tolerability, and feasibility of young plasma infusion in the plasma for Alzheimer symptom amelioration study: a randomized clinical trial. JAMA Neurol 2019; 76 ( 1 ): 35 - 40. https://doi.org/10.1001/jamaneurol.2018.3288
dc.identifier.citedreferenceLees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet 2009; 373 ( 9680 ): 2055 - 2066. https://doi.org/10.1016/S0140-6736(09)60492-X
dc.identifier.citedreferenceXie A, Gao J, Xu L, Meng D. Shared mechanisms of neurodegeneration in Alzheimer’s disease and Parkinson’s disease. Biomed Res Int 2014; 2014: 648740. https://doi.org/10.1155/2014/648740
dc.identifier.citedreferenceShahani L, Singh S, Khardori NM. Immunotherapy in clinical medicine: historical perspective and current status. Med Clin North Am 2012; 96 ( 3 ): 421 - 431, ix. https://doi.org/10.1016/j.mcna.2012.04.001
dc.identifier.citedreferenceKeller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000; 13 ( 4 ): 602 - 614. https://doi.org/10.1128/cmr.13.4.602-614.2000
dc.identifier.citedreferenceLuke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta- analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145 ( 8 ): 599 - 609. https://doi.org/10.7326/0003-4819-145-8-200610170-00139
dc.identifier.citedreferenceMarano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus 2016; 14 ( 2 ): 152 - 157. https://doi.org/10.2450/2015.0131-15
dc.identifier.citedreferenceZhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. New Eng J Med 2007; 357 ( 14 ): 1450 - 1451. https://doi.org/10.1056/NEJMc070359
dc.identifier.citedreferenceCheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24 ( 1 ): 44 - 46. https://doi.org/10.1007/s10096-004-1271-9
dc.identifier.citedreferenceKo J- H, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther (Lond) 2018; 23 ( 7 ): 617 - 622. https://doi.org/10.3851/IMP3243
dc.identifier.citedreferenceDuan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID- 19 patients [published online ahead of print April 6, 2020]. Proc Natl Acad Sci U S A. https://doi.org/10.1073/pnas.2004168117
dc.identifier.citedreferenceShen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID- 19 with convalescent plasma [published online ahead of print 2020]. JAMA. https://doi.org/10.1001/jama.2020.4783
dc.identifier.citedreferenceBloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID- 19 [published online ahead of print April 7, 2020 ]. J Clin Invest. https://doi.org/10.1172/JCI138745
dc.identifier.citedreferenceLünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology- mode of action and clinical efficacy. Nat Rev Neurol 2015; 11 ( 2 ): 80 - 89. https://doi.org/10.1038/nrneurol.2014.253
dc.identifier.citedreferenceDeng J, Zhou F, Wong CY, Huang E, Zheng E. Efficacy of therapeutic plasma exchange for treatment of autoimmune hemolytic anemia: a systematic review and meta- analysis of randomized controlled trials. J Clin Apher. Published online May 8, 2020. https://doi.org/10.1002/jca.21790
dc.identifier.citedreferenceKulkarni R. Antibody- dependent enhancement of viral infections. dynamics of immune activation in viral diseases. In: Bramhachari P, editor. Dynamics of Immune Activation in Viral Diseases. Singapore: Springer; 2019: 9 - 41. https://doi.org/10.1007/978-981-15-1045-8_2
dc.identifier.citedreferencePapa SM, Brundin P, Fung VSC, et al. Impact of the COVID- 19 pandemic on Parkinson’s disease and movement disorders. Mov Disord 2020; 35 ( 5 ): 711 - 715. https://doi.org/10.1002/mds.28067
dc.identifier.citedreferenceHelmich RC, Bloem BR. The impact of the COVID- 19 pandemic on Parkinson’s disease: hidden sorrows and emerging opportunities. J Parkinson Dis 2020; 10 ( 2 ): 351 - 354. https://doi.org/10.3233/JPD-202038
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
mds28198_am.pdf
Size:
3.231MB
Format:
PDF
View/Open
Name:
mds28198.pdf
Size:
196.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.